These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23835020)

  • 1. Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease.
    Andrieux K; Couvreur P
    Ann Pharm Fr; 2013 Jul; 71(4):225-33. PubMed ID: 23835020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
    Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nanoparticles for brain delivery of drugs or contrast agents. Application to Alzheimer's disease].
    Andrieux K; Couvreur P
    Biol Aujourdhui; 2012; 206(3):185-90. PubMed ID: 23171841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer's Disease.
    Ma TJ; Gao J; Liu Y; Zhuang JH; Yin C; Li P; Mao L; Xu J; Xu YX; Li YP; Zhao ZX; Yin Y
    Mini Rev Med Chem; 2018; 18(12):1035-1046. PubMed ID: 29243575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine for the treatment of Alzheimer's disease.
    Gregori M; Masserini M; Mancini S
    Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blood-brain barrier and Alzheimer's disease].
    Kuwahara H; Nishida Y; Yokota T
    Brain Nerve; 2013 Feb; 65(2):145-51. PubMed ID: 23399672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
    Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C
    J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult neurogenesis: a potential tool for early diagnosis in Alzheimer's disease?
    Lopez-Toledano MA; Ali Faghihi M; Patel NS; Wahlestedt C
    J Alzheimers Dis; 2010; 20(2):395-408. PubMed ID: 20164555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy.
    Tosi G; Pederzoli F; Belletti D; Vandelli MA; Forni F; Duskey JT; Ruozi B
    Prog Brain Res; 2019; 245():57-88. PubMed ID: 30961872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
    Ling S; Zhou J; Rudd JA; Hu Z; Fang M
    Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
    Shoji M
    Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.
    Bates KA; Verdile G; Li QX; Ames D; Hudson P; Masters CL; Martins RN
    Mol Psychiatry; 2009 May; 14(5):469-86. PubMed ID: 18794889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorinated Molecules and Nanotechnology: Future 'Avengers' against the Alzheimer's Disease?
    Dabur M; Loureiro JA; Pereira MC
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease pathogenesis and therapeutic interventions.
    Parihar MS; Hemnani T
    J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.